Professional Marketing brief: September 2012

Share this article:
Professional Marketing brief: September 2012
Professional Marketing brief: September 2012

Novartis and the University of Pennsylvania have created an alliance to research and develop targeted chimeric antigen receptor (CAR) immunotherapies to treat cancer. Novartis gained exclusive rights to the investigational therapy CART-19, which Penn has begun piloting. The experimental treatments target a protein linked to B-cell malignancies such as chronic lymphocytic leukemia and diffuse large B-cell lymphoma.

Johnson & Johnson has reached an agreement in principle regarding Risperdal allegations, the Wall Street Journal reported. The Journal estimates the agreement could hit $2.2 billion. Johnson & Johnson has been sued over alleged infractions that include encouraging off-label use for the anti-psychotic and improper marketing tactics.

GlaxoSmithKline's $3.6-billion offer for Human Genome Sciences came with an added price. As first reported by the Washington Post, upon the closing of the offer, several HGS board members resigned and were replaced with GSK executives. And following the appointment of the GSK designees, “the HGS Board removed all of the executive officers of HGS,” notes the tender offer statement GSK filed with the SEC.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?